Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 2

Time frame: From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 29 months

Overall Survival (OS)

Time frame: From the first dose of treatment to the date of death, regardless of the actual cause of the subject's death, assessed up to 29 months

Progression Free Survival (PFS) per RECIST v1.1/mRECIST

Time frame: From first dose of treatment until progression per RECIST 1.1/ mRECIST as assessed by the Investigator or death due to any cause prior to progression, assessed up to 15 months

Objective Response Rate (ORR) per RECIST 1.1/ mRECIST

Time frame: Until progression, assessed up to 15 months

Disease Control Rate (DCR) per RECIST 1.1/ mRECIST

Time frame: Until progression, assessed up to 15 months

Rate of Adverse Events

Time frame: From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 29 months

Duration of response (DoR) per RECIST 1.1/mRECIST

Time frame: From the first dose, until progression, assessed up to 15 months